Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,354.06 357.25 2.55%
TOPIX 1,160.59 24.50 2.16%
HANG SENG 22,813.92 142.66 0.63%

Novo Nordisk A/S: Novo Nordisk receives Complete Response Letter in the US for Tresiba(R) and Ryzodeg(R)


Novo Nordisk A/S: Novo Nordisk receives Complete Response Letter in the US for Tresiba(R) and Ryzodeg(R)

BAGSVAERD, DENMARK -- (Marketwire) -- 02/10/13 --

Company announcement No 11 / 2013:

http://hugin.info/2013/R/1676898/546736.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and

other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1676898]

Further information: Media: Mike Rulis +45 3079 3573 mike@novonordisk.com

Lori Moore +1 609 919 7991 lrmo@novonordisk.com

Investors: Kasper Roseeuw Poulsen +45 4442 4303 krop@novonordisk.com

Frank Daniel Mersebach +45 4442 0604 fdni@novonordisk.com

Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com

Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement